Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
ID: 351495Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351495

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-016.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)." This initiative invites exploratory and developmental research grant applications aimed at creating novel informatics methods and algorithms that enhance data acquisition, analysis, visualization, and interpretation across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The NIH emphasizes the importance of innovative approaches that can significantly advance cancer research technology, with a total funding amount of approximately $1,020,000 available for about five awards, each with a maximum budget of $275,000 for a project duration of up to two years. Interested applicants must submit their proposals by 5:00 PM local time on November 15, 2024, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-016-Full-Announcement.html
    RFA-CA-24-016.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) aimed at encouraging exploratory and developmental research (R21) focused on innovative informatics methods and algorithms for cancer research and management. This initiative, linked to the National Cancer Institute (NCI) and reissuing RFA-CA-23-014, invites applications that enhance data acquisition, analysis, and interpretation across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The funding opportunity supports projects with transformative potential, prioritizing innovative informatics approaches over traditional data generation. Key dates include an application opening on May 11, 2024, with applications due by 5:00 PM local time. It anticipates funding approximately five awards totaling $1,020,000 for a maximum project duration of two years, with a budget cap of $275,000. Eligible applicants include a diverse range of institutions, and strong emphasis is placed on novel algorithms that can be widely adopted in the cancer research community. Compliance with submission guidelines and proper registrations is critical, as incomplete or non-compliant applications will not be reviewed. The initiative underscores the NIH’s focus on enhancing cancer research technology through innovative solutions.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. The initiative focuses on three key areas: the application of new cancer communication surveillance methods, the development of rapid pilot interventions, and the creation of multilevel communication models that emphasize bidirectional influences in cancer prevention and control. This funding, available through R21 exploratory/developmental grants, provides up to $275,000 for a maximum of two years, with applications due starting January 16, 2025. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)" aimed at advancing research in computational genomics, bioinformatics, and data visualization methodologies that enhance genomic science and its application to human health. This initiative seeks innovative projects that develop novel analytical tools and methodologies, with a budget limit of $275,000 for a two-year project period, focusing on scalable solutions applicable across various diseases and biological systems. The funding is particularly targeted at underrepresented entities in genomic research, including higher education institutions, nonprofits, and governmental bodies, reflecting NIH's commitment to fostering collaborative research in this critical field. Interested applicants should note that key submission dates begin on January 16, 2025, with a final expiration date of September 8, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.